

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
30 December 2021 (30.12.2021)



(10) International Publication Number
WO 2021/262779 A1

(51) International Patent Classification:

A61P 25/24 (2006.01) C07D 401/12 (2006.01)
C07D 213/40 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2021/038564

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

(22) International Filing Date:

23 June 2021 (23.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

Published:

- with international search report (Art. 21(3))

(30) Priority Data:

63/043,075 23 June 2020 (23.06.2020) US

(71) Applicant: **BIOHAVEN THERAPEUTICS LTD.**
[US/US]; 215 Church Street, New Haven, Connecticut
06510 (US).

(72) Inventors: **BERMAN, Robert**; Biohaven Therapeutics
Ltd., 215 Church Street, New Haven, Connecticut 06510
(US). **KUMAR, Rajesh**; Biohaven Therapeutics Ltd., 215
Church Street, New Haven, Connecticut 06510 (US).
CONWAY, Charles M.; Biohaven Therapeutics Ltd.,
215 Church Street, New Haven, Connecticut 06510 (US).
DONOHUE, Mary K.; Biohaven Therapeutics Ltd., 215
Church Street, New Haven, Connecticut 06510 (US). **RE-**
KA, Ajaya Kumar; Biohaven Therapeutics Ltd., 215
Church Street, New Haven, Connecticut 06510 (US).

(74) Agent: **ZUEV, Dmitry**; Biohaven Therapeutics Ltd., 215
Church Street, New Haven, Connecticut 06510 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: TOPICAL FORMULATIONS OF (1S)-1-PHENYL-2-PYRIDIN-2-YLETHANAMINE

(57) Abstract: Provided is a pharmaceutical formulation including (1S)-1-phenyl-2-pyridin-2-ylethanamine, a pharmaceutically acceptable salt thereof, a solvate thereof, or a prodrug thereof; and a pharmaceutically acceptable topical carrier. Also provided is a method for treating neuropathic pain by administering to a patient in need of such treatment a therapeutically effective amount of the pharmaceutical formulation.



WO 2021/262779 A1